MariaBaerMD

Professor of Hematology & Oncology, University MD School of Medicine

Overview of Dr. Baer

Dr. Maria Baer is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including University of Maryland Medical Center, University of Maryland Baltimore Washington Medical Center, and Veterans Affairs Maryland Health Care System-Baltimore Division. She received her medical degree from Johns Hopkins University School of Medicine and has been in practice 38 years. Dr. Baer accepts several types of health insurance, listed below. She is one of 30 doctors at University of Maryland Baltimore Washington Medical Center and one of 100 doctors at University of Maryland Medical Center who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
22 S Greene St
Baltimore, MD 21201
Book by Phone+1(443) 348-0771

Fax+1 410-328-6896

Education & Training

Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
Vanderbilt University Medical CenterResidency, Internal Medicine, 1979 - 1982
Johns Hopkins University School of MedicineClass of 1979

Certifications & Licensure

MD State Medical License 2007 - 2026
NY State Medical License 1985 - 2008
TN State Medical License 1984 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 1998 Jan 01
Completed
Phase 3
Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer Start of enrollment: 2002 Mar 01
Completed
Phase 2
Combination Chemotherapy Followed By Filgrastim or Sargramostim in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Start of enrollment: 1999 Jan 01
Completed
Phase 2
Irinotecan and Cytarabine in Treating Patients With Refractory or Recurrent Acute Myeloid Leukemia or Chronic Myelogenous Leukemia Start of enrollment: 1999 Nov 01
Completed
Phase 1
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML Start of enrollment: 2004 Apr 01
Completed
Phase 2
Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
Completed
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia Start of enrollment: 2006 Oct 01
Active, not recruiting
Study of Bone Marrow and Blood Samples in Patients With Untreated Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Enrolled on Clinical Trial CALGB-9621 or CALGB-9720 Start of enrollment: 1997 Mar 15
Completed
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 3
A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 3
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia Start of enrollment: 2013 Oct 01
Terminated
Phase 2
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Start of enrollment: 2013 Aug 01
Completed
Phase 3
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia Start of enrollment: 2014 May 19
Active, not recruiting
Phase 3
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses Start of enrollment: 2015 Jun 30
Active, not recruiting
Phase 2
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Start of enrollment: 2016 Nov 02
Active, not recruiting
Phase 1, Phase 2
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia Start of enrollment: 2018 Oct 04
Active, not recruiting
Phase 3
Roles: Principal Investigator
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2020 Oct 23
Active, not recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

202 citations
Drug resistance: Still a daunting challenge to the successful treatment of AML
Brian C. Shaffer, Jean-Pierre Gillet, Chirayu Patel, Maria R. Baer, Susan E. Bates
Drug Resistance Updates. 2012-02-01
314 citations
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
Krzysztof Mrózek, Guido Marcucci, Deedra Nicolet, Kati Maharry, Heiko Becker
Journal of Clinical Oncology. 2012-12-20
129 citations
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled,...
Guillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, Maria R. Baer, Mikkael A. Sekeres
The Lancet. Oncology. 2016-04-01

Abstracts/Posters

Association of Time to Initial Emergency Department Analgesia with Rate of Admission in Patients with Uncomplicated Sickle Cell Disease Vaso-Occlusive Crises
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at E...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Na¥ve Patients with Higher-Risk Myelodysplastic Syndrome
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral TrialCl...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
A 14q32.31 Genomic-Imprinted DLK1-DIO3 microrna promotes Leukemogenesis By Inducing Stem Cell Quiescence and Inhibiting NK Cell Anti-Cancer Immunity
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
PP2A Activators Enhance Efficacy of FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells through AKT Inactivation-Dependent Pim-1 and c-Myc Proteasomal Degradation
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP In...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Precision Medicine Treatment in Older AML: Results of Beat AML Master TrialClinically Relevant Abstract
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
Maria R. Baer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with N...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Join now to see all

Press Mentions

New Drug Combination Targets Aggressive Blood CancerMarch 7th, 2017
Researchers Identify Novel Mechanism in Combination Drug Therapy for Acute Myeloid Leukemia, Other CancersOctober 11th, 2016

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment